Blockchain Registration Transaction Record

Novogenia Launches Expanded MGT Plus Methylation Test in U.S. with 10X Health

Novogenia launches MGT Plus methylation test in U.S. with 10X Health, analyzing 27 genes for comprehensive insights into metabolic, stress, and immune pathways, advancing personalized prevention.

This news matters because it represents a significant step forward in personalized medicine. The MGT Plus test offers a more comprehensive analysis of methylation-related genes, which can lead to better prevention and treatment strategies tailored to individual genetic profiles. For consumers, this means access to deeper insights into their health, potentially enabling proactive management of conditions related to metabolism, stress, and immune function. For healthcare providers, it provides a powerful tool to customize patient care. Moreover, the expansion into the U.S. market highlights the growing demand for direct-to-consumer genetic testing, making such advanced diagnostics more accessible. As the market for genetic testing continues to grow, innovations like MGT Plus are likely to become integral to routine health assessments, empowering individuals to take charge of their health with actionable information.